Skip to main content

Table 11 CSS analysis for patients after PSM

From: The platelet to lymphocyte ratio is a potential inflammatory marker predicting the effects of adjuvant chemotherapy in patients with stage II colorectal cancer

Characteristics

 

RMSTb (95%CI)

HRc (95%CI)

P valuea

Interaction p

Non-chemotherapy

Chemotherapy

Total

–

53.3 (51.0–55.1)

56.0 (53.8–57.5)

0.684 (0.332–1.409)

0.300

–

Sex

Male

52.0 (48.4–54.6)

55.9 (53.2–57.7)

0.420 (0.169–1.042)

0.053

0.026

Female

55.0 (51.1–57.3)

56.1 (52.2–57.9)

1.926 (0.478–7.762)

0.349

 

Age (years)

≤55

53.8 (46.5–57.4)

56.6 (50.4–58.9)

0.435 (0.079–2.388)

0.324

0.196

56–60

54.6 (45.3–58.2)

57.1 (49.9–59.2)

0.458 (0.041–5.054)

0.513

 

61–65

53.2 (46.3–57.0)

55.6 (48.5–58.1)

0.789 (0.158–3.949)

0.772

 

66–70

54.2 (48.5–57.3)

57.5 (52.7–59.1)

0.182 (0.020–1.645)

0.086

 

> 70

52.0 (47.2–55.3)

53.9 (48.5–56.5)

1.660 (0.468–5.887)

0.427

 

Location

Rectum

52.4 (48.7–54.9)

54.6 (51.3–56.8)

0.738 (0.297–1.836)

0.511

0.797

Colon

54.5 (50.3–56.8)

57.5 (54.8–58.8)

0.634 (0.192–2.087)

0.449

 

Size (cm)

≤5.0

54.3 (50.6–56.5)

56.7 (54.0–58.2)

0.846 (0.295–2.425)

0.756

0.116

> 5.0

52.6 (48.8–55.5)

55.1 (51.6–57.3)

0.641 (0.228–1.802)

0.395

 

Differentiation

Well-moderate

53.5 (50.8–55.5)

56.1 (54.2–57.5)

0.703 (0.329–1.504)

0.361

0.864

Poor

50.5 (36.0–56.7)

53.8 (38.2–58.6)

0.574 (0.050–6.560)

0.651

 

T category

3

58.1 (54.1–59.4)

57.3 (54.3–58.9)

3.306 (0.367–29.738)

0.258

0.042

4

50.9 (47.3–53.6)

55.2 (52.3–57.0)

0.517 (0.228–1.172)

0.107

 

CEAd (ng/mL)

< 5

55.2 (51.9–57.2)

57.3 (54.3–58.7)

0.785 (0.239–2.573)

0.688

0.897

≥5

52.4 (47.5–55.8)

55.0 (51.4–57.2)

0.667 (0.203–2.195)

0.502

 

Examined lymph nodes

< 12

50.7 (43.8–54.8)

51.7 (45.5–55.2)

1.620 (0.487–5.393)

0.427

0.107

≥12

54.1 (51.1–56.0)

57.5 (55.6–58.7)

0.359 (0.128–1.007)

0.042

 

PLRe

≤130

55.3 (51.8–57.4)

54.9 (51.9–56.8)

0.963 (0.379–2.449)

0.938

0.231

> 130

51.3 (47.4–54.1)

57.6 (54.7–58.9)

0.372 (0.100–1.374)

0.122

 
  1. a P value of the log-rank test
  2. b RMST: the restricted mean survival time
  3. c HR: Hazard Ratio, chemotherapy patients vs. non-chemotherapy patients
  4. d CEA: carcinoembryonic antigen
  5. e PLR: platelet to lymphocyte ratio
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us